CAMBRIDGE, Mass. –– Gen9, Inc., a pioneer in synthetic biology and leader in the development of scalable technologies for synthesizing and assembling DNA, today announced the appointment of Leda Notchey as Vice President of Marketing and Matt Marano as Senior Director of Business Development.

“We are pleased to welcome Leda and Matt to the Gen9 team. Their extensive experience in the life sciences industry will be a tremendous asset as we accelerate our presence in key markets for synthetic biology, including biomedical research, agriculture, pharmaceuticals, chemicals, biofuels, and flavors and fragrances,” said Chief Executive Officer Kevin Munnelly. “Gen9 is poised to play a leading role in providing the rationally-designed, engineered DNA that will be the foundation for environmentally-responsible, efficient manufacturing in the 21st century. I am thrilled that Leda and Matt have joined Gen9 during this transformative time in our industry. ”

In her new role, Ms. Notchey will oversee Gen9?s strategic marketing functions, including market development, product management, brand, and corporate communications. Ms. Notchey brings more than 20 years of experience in life sciences marketing, business leadership and commercial operations. She joins Gen9 from Thermo Fisher Scientific where she was most recently Director of Global Channel Development, Biosciences. Previously, she was Director of Strategic Marketing for Thermo Fisher’s Laboratory Products business. Ms. Notchey has also held senior marketing positions at Codon Devices and PerkinElmer. She has a Bachelor of Science in microbiology from the University of Massachusetts, Amherst.

Mr. Marano will be responsible for expanding Gen9?s strategic alliances and customer engagements through partnerships that leverage Gen9’s high-throughput DNA manufacturing capabilities and R&D pipeline. Mr. Marano brings significant experience in business development, corporate account management and sales in diagnostics, life sciences and healthcare markets. He served as Director of Business Development at Archimedes, Inc., where he developed and led the company’s commercial expansion into Europe, and also held positions at BioTrove, CODA Genomics, Invitrogen, Ardais Corporation, BioRobotics, Packard Instrument, and Molecular Dynamics. He has a Bachelor of Science in biology from Providence College.

Gen9 has developed unique, next-generation technologies for synthesizing and assembling DNA constructs for use in numerous synthetic biology applications, including antibody, peptide and enzyme engineering; gene and pathway building; and genome construction. The company’s innovative BioFab® platform enables the production of high-quality synthetic DNA constructs at an unprecedented scale. Gen9 is the leader in the area of next generation gene synthesis, and continues to focus on innovation, collaboration, dedication and integrity in all aspects of its work.

More information can be found at www.Gen9Bio.com.

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.

Gen9, GeneBit, GeneByte and BioFab are trademarks or registered trademarks of Gen9, Inc. All other brands may be trademarks of their respective holders.